Showing results (81-90 of 240) with videos related to

Sort By:
Pageof 24
Journal of Thrombosis and Haemostasis : JTH|March 19, 2016
Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgeryA C Spyropoulos, A Al-Badri, M W Sherwood, et al.
Nucleic Acids Research|June 25, 2004
PRED-TMBB: a web server for predicting the topology of beta-barrel outer membrane proteinsPantelis G Bagos, Theodore D Liakopoulos, Ioannis C Spyropoulos, et al.
Hospital Practice (1995)|November 25, 2017
Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxisCharles E Mahan, Allison E Burnett, Meghan L Fletcher, et al.
Bioinformatics (Oxford, England)|June 18, 2004
TMRPres2D: high quality visual representation of transmembrane protein modelsIoannis C Spyropoulos, Theodore D Liakopoulos, Pantelis G Bagos, et al.
Chest|July 13, 2002
Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparinAlex C Spyropoulos, Judith S Hurley, Gabrielle N Ciesla, et al.
BMC Bioinformatics|December 28, 2004
A database for G proteins and their interaction with GPCRsAntigoni L Elefsinioti, Pantelis G Bagos, Ioannis C Spyropoulos, et al.
Thrombosis Research|September 8, 2019
Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costsAlex C Spyropoulos, Veronica Ashton, Yen-Wen Chen, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 1, 2016
Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?Alex C Spyropoulos, Ron Preblick, Winghan J Kwong, et al.
American Heart Journal|April 14, 2019
Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillationEric D Peterson, Veronica Ashton, Yen-Wen Chen, et al.
Thrombosis and Haemostasis|November 27, 2015
European Union-28: An annualised cost-of-illness model for venous thromboembolismStefano Barco, Alex L Woersching, Alex C Spyropoulos, et al.
Pageof 24